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a  b  s  t  r  a  c  t
The purpose of the study is to show the evolution of renal replacement therapy (RRT) in
Spain from 2007 to 2013.
Aggregated data and individual patient records were used from participating regional
renal  disease registries and that National Transplant Organisation registry. The reference
population was the ofﬁcial population on January 1st of each year studied. Data on incidence
and  prevalence were based on aggregated data, while the survival analysis was calculated
from individual patient records. The study period was 2007–2013 for prevalence, incidence
and transplantation, and survival was analysed for 2004–2012. The population covered by
the  registry was a minimum of 95.3–100% of the Spanish population for aggregated data.
The  EU27 age and gender distributions of the European population for 2005 were used to
adjust incidence and prevalence for age and gender. Survival probabilities were calculated
for  incident patients between the years 2004 and 2013 using the Kaplan–Meier method to
calculate unadjusted patient survival probability. The log rank test was applied to compare
survival curves according to some risk factors. Cox proportional hazards model was created
to  study the potential predictors of survival.
In 2013, the total number of patients in Spain that started RRT was 5705 for 95.3% of the
total  Spanish population, with an unadjusted rate of 127.1 PMP. The evolution from 2007 to
2013 showed a gradual decline from 127.4 PMP in 2007 to 120.4 PMP in 2012, with a small
upturn to 127.1 in 2013. The adjusted incidence rate for the year 2013 was 121.5 PMP for the
total  population, 158.7 PMP for males and 83.1 PMP for females. The most frequent cause of
primary renal disease in incident was diabetes mellitus: 20.4% in 2007, which increased to
24.6% in 2013. The percentage of transplant as ﬁrst RRT increased from 1.7% in 2007 to 4.2%
in  2013. The total number of patients in RRT for 95.3% of the population in 2013 was 50,567,
with  an unadjusted prevalent rate of 1125.7 PMP. The adjusted prevalence rate for 2013 was
1087.5  PMP (1360.7 PMP for males and 809.8 PMP for females). The percentage of diabetes
mellitus in prevalent patients evolved from 13.9% in 2007 to 14.9% (168 PMP) in 2013. Thepercentage of transplanted prevalent patients with functioning grafts evolved from 49.3%
in  2007 to 51.5% in 2013. The number of transplantations performed each year increased
from  2211 (48.9 PMP) in 2007 (6.2% living donor transplants) to 2552 (54.2 PMP) in 2013 (15.0%
living donor transplants).
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40,394 patients from 12 regions of Spain who began RRT between 2004 and 2012 were
included in the survival analysis (87% Spanish population coverage). Unadjusted patient
survival probabilities after one, 2 and 5 years were 91, 81 and 57%, respectively. In the uni-
variate analysis, better survival was found for non-diabetic patients, women, age below 45,
peritoneal dialysis as ﬁrst RRT and patients who had received at least one transplant.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).










r  e  s  u  m  e  n
El objetivo del estudio es mostrar la evolución del TRS en Espan˜a desde 2007 hasta 2013.
Se  utilizaron datos agregados y registros individuales de pacientes de los registros de
enfermedades renales de las comunidades autónomas participantes, y el registro de la Orga-
nización Nacional de Trasplantes. La población de referencia fue la población oﬁcial a 1 de
enero de cada an˜o estudiado. La incidencia y la prevalencia se basan en datos agregados,
mientras que el análisis de supervivencia se calculó a partir de registros individuales. El
período de estudio fue 2007-2013 para prevalencia, incidencia y trasplante; y 2004-2012 para
el  análisis de supervivencia. La población cubierta por el registro fue un mínimo del 95,3-
100% de la población espan˜ola para datos agregados. La distribución de edad y sexo de la
población europea (UE-27) para el an˜o 2005 se utilizó para ajustar incidencia y prevalencia.
Se  calcularon las probabilidades de supervivencia de los pacientes incidentes entre 2004 y
2013, utilizando el método de Kaplan-Meier para calcular la probabilidad de supervivencia
sin  ajustar. Las curvas de supervivencia se compararon mediante log rank test de acuerdo
con  algunos factores de riesgo. Se construyó un modelo proporcional de Cox para estudiar
los  posibles predictores de supervivencia.
En 2013 el número total de pacientes en Espan˜a que iniciaron TRS fue de 5.705 para un
95,3%  del total de la población espan˜ola; con una tasa no ajustada de 127,1 pmp.  La evolución
desde 2007 hasta 2013 mostró una disminución gradual, de 127,4 pmp en 2007 a 120,4 pmp
en  2012, con un pequen˜o repunte a 127,1 en 2013. La incidencia ajustada para el an˜o 2013
fue  de 121,5 pmp total, 158,7 pmp para hombres y 83,1 pmp para mujeres. La causa más
frecuente de enfermedad renal primaria en incidentes fue la diabetes mellitus: el 20,4%
en  2007, aumentando al 24,6% en 2013. El porcentaje de trasplante, como primera TRS,
aumentó del 1,7% en 2007 al 4,2% en 2013. El número total de pacientes en TRS, respecto
al  95,3% de la población, en 2013 fue de 50.567, con una tasa de prevalencia no ajustada
de  1.125,7 pmp. La tasa de prevalencia ajustada para 2013 fue 1.087,5 pmp, 1.360,7 pmp para
varones y 809,8 pmp para mujeres. El porcentaje de diabetes mellitus en pacientes preva-
lentes evolucionó del 13,9% en 2007 al 14,9% en 2013. El porcentaje de pacientes prevalentes
trasplantados y con injerto funcionante pasó del 49,3% en 2007 al 51,5% en 2013. El número
de  trasplantes realizado cada an˜o aumentó de 2.211 (48,9 pmp) en 2007, con un 6,2% de
trasplantes de donante vivo, a 2.552 (54,2 pmp) en 2013, con un 15% de trasplantes de
donante vivo.
Se incluyeron en el análisis de supervivencia 40.394 pacientes procedentes de 12 regiones
que  comenzaron su TRS entre 2004 y 2012 (un 87% de cobertura de la población espan˜ola). Las
probabilidades de supervivencia sin ajustar de los pacientes, a uno, 2 y 5 an˜os, fueron del 91,
81  y 57% respectivamente. En el análisis univariado se encontró una mejor supervivencia
en  pacientes no diabéticos, de sexo femenino, edad inferior a 45 an˜os, siendo la diálisis
peritoneal el primer TRS y que hubieran recibido al menos un trasplante.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
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ntroduction
ince the publication of the 2006 Spanish Renal Registry (REER)
eport in Nefrología1 in 2009, we have not published any addi-
ional report, although we have presented a yearly report at
he Spanish Society of Nephrology (SEN) Congress. Also the
nformation has been available in the website of the SEN2
s a presentation. During these years we have also devel-
ped our own website3 that collects annual incidence and
revalence data separated by modality of renal replacement
reatment (RRT) including each autonomous regions (ARs) of
pain and the global data for Spain. We  maintain our col-
aboration with the European ERA-EDTA registry4 and with
he North American USRDS registry,5 as the reference from
pain. Since 2012 (2011 report),6 the yearly report at the
EN Congress includes survival data in patients in RRT since
004, compiling data from the ARs registries that was made
vailable.
In recent years, a new codiﬁcation of primary renal dis-
ase (PRD) has been developed by the ERA-EDTA Registry,
ith the collaboration of one member of our REER. Subse-
uently, the REER collaborated in its translation into Spanish
ublished in Nefrología.7 The new coding provides a sim-
ler system to achieve a more  precise diagnosis of renal
isease, including codes and terms for most renal diseases
hether or not may progress end-stage renal failure. It also
as the advantage of including the latest advances on renal
isease, as well as a direct link to CIE-10 codes and SNOMED
dentiﬁers.
The aim of the present REER report is to illustrate the sit-
ation of end-stage renal disease (ESRD) in Spain in 2013.
hrough analysis of the evolution of the epidemiological
arameters during recent years, we  want to outline the possi-
le evolution of the disease and RRT in the near future.
ethodology
ources  of  data
 Annual collection of aggregated and individualised data
from the renal registries of the participating ARs. It was not
possible to include data from the autonomous region of the
Canary Islands in 2013 since in 2013 and 2014 the databases
and electronic storage medium were being transferred to
the Canary Islands Health Service, which is now analysing
the registry.
 Donation and transplant registry of the Spanish Transplant
Organisation.
 Reference population of Spain and each autonomous
region: the ofﬁcial data on population is provided on 1 Jan-
uary of the year, published by the Spanish Ofﬁcial State
Bulletin (BOE).8–14 Distribution of population by age group,
obtained from the Spanish Statistical Ofﬁce (INE) website.15The incidence and prevalence data were calculated based
n the aggregated data, while the survival analysis was per-
ormed based on the data on individual patients from the
egistries provided by the autonomous regions. 6(2):97–120 99
Study  period
• 2007–2013 for prevalence, incidence and transplants.
• 2004–2012 for the survival analysis.
Deﬁnitions
The deﬁnitions used were those agreed upon by the Span-
ish Group of Registries of Renal Diseases (GRER)16 and, if not
available, the deﬁnitions of the ERA-EDTA Registry.17
• Incidence: Number of patients who started RRT during the
speciﬁed period; in this report it was in a year period during
2007–2013.
• Prevalence: Total number of alive patients in RRT on 31
December of the corresponding year with residence in each
of the ARs.
Incidence and prevalence rates are expressed as patients
per million of the population (PMP).
Methods
Rates  of  incidence  and  prevalence
• Non adjusted rates: number of incident or prevalent
patients divided by the general population in the speciﬁc
year and multiplied by one million. The rates are presented
stratiﬁed by PRD, type of replacement therapy, sex and age
group.
• Adjusted rates: We use the distribution by age and gender
of the European population in 2005 (EU27)18 for the total
in Spain and each AR to adjust the rates using the direct
method.
Kidney  transplants  performed
The number of kidney transplants was recorded from
the donation and transplant registry of the Spanish
Transplant Organisation19 and the data was presented
stratiﬁed by donor type (living, deceased by neurological
criteria—brain death—or deceased by circulatory and respi-
ratory criteria—asystole).
Methods  for  survival  analysis
It was based on data on individual patients provided by  the
ARs with speciﬁc consent to be use for analysis. To merge  all
data, an initial process of data purging and conversion was
performed until a uniform format was obtained that allowed
the analysis of variables.
Patients incident between 2004 and 2012, over 15 years of
age and with a follow-up greater than 3 months were included.
Patients with a kidney transplant as a ﬁrst RRT and patients
from other registries were excluded.
For description of the patients included in the survival anal-
ysis, mean, median and standard deviation were used for the
quantitative variables and percentages and frequencies were
used for the categorical variables. The Kaplan–Meier method
was used to calculate the unadjusted probability of survival,
and the log-rank test was used to compare the survival curves
between groups. A Cox proportional hazards model was devel-
oped to study factors potentially predictive of survival using
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Table 1 – Coverage of the population of Spain by the REER.
Year
2007 2008 2009 2010 2011 2012 2013
Population 45,200,737 46,157,822 46,745,807 47,021,031 47,190,493 47,265,321 47,129,700
Population covered 43,415,981 44,296,880 44,804,102 45,559,052 47,095,618 47,265,321 44,916,825
% Coverage 96.1 96 95.8 96.9 99.8 100 95.3REER: The Spanish Renal Registry.
the following as adjustment variables: age, sex, RRT modality,
diabetic nephropathy as PRD and having received at least one
transplant.
Death was considered to be an event, censoring the recov-
ery of renal function, transfer to another registry and the loss
to follow-up. The analysis was done by intention to treat.
The software programs used were Microsoft Excel and SPSS
v.15.0 for Windows.
Results
The total population covered by the registry has varied from
year to year, from at least 95.3% to 100% of the total popula-
tion in Spain for the aggregated incidence and prevalence data
(Table 1).Incidence
In 2013 the total number of patients who started RRT due
to ESRD was 5705, for a 95.3% of the total population of
Table 2 – Incidence by gender and initial renal replacement trea
Total 
N 
Population N PMP Male Fem
Andalusia 8,440,300 1043 123.6 655 38
Aragon 1,347,150 168 124.7 112 5
Asturias 1,068,165 169 158.2 121 4
Balearic Islandsa 1,017,395 144 141.5 91 5
Cantabria 591,888 63 106.4 46 1
Castile and León 2,519,875 270 107.1 197 7
Castile-La Mancha 2,100,998 215 102.3 136 7




5,113,815 683 133.6 434 24
Extremadura 1,104,004 137 121.4 97 4
Galicia 2,765,940 393 142.1 264 12
Madrid 6,495,551 780 120.1 505 27
Murcia 1,472,049 160 108.7 107 5
Navarra 644,477 69 107.1 48 2
Basque Country 2,191,682 262 119.5 183 7
La Rioja 322,027 37 114.9 22 1
Ceutab 84,180 12 142.6 7 
Melillab 83,679 8 95.6 4 
Total in Spain 44,916,825 5708 127.1 3746 195
PD: peritoneal dialysis (all modalities); HD: haemodialysis (all modalities); 
ETX: early kidney transplant.
a The population covered on the Balearic Islands excludes the population
b The autonomous cities of Ceuta and Melilla provide care for patients froSpain. This represents an unadjusted rate of 127 PMP.  The low-
est rate was in Castilla-La Mancha with 102.3 PMP,  and the
highest rate was that of Asturias with 158.2 PMP  (Table 2).
Among incident patients, 3746 (65.7%) were men  and 1959
(34.3%) were women, and the rate was 200.9 PMP  for men  and
102.4 PMP  for women (Table 2), so in Spain, for every woman
that started RRT, there were 1.9 men  who did so. The value
varied according to AR; from 1:1 in Melilla up to 2.7 men  for
each woman in Cantabria and in Castilla y León. By age group,
the incidence increased in both men  and in women, reaching
414.9 PMP  in patients over 75 years of age (Table 3). The age-
adjusted incidence rate was 121.5 PMP overall, 158.7 PMP  for
men  and 83.1 for women, with a wide variation among ARs
(Table 4 and Fig. 1).
As far as RRT modality, in 2013, 78.9% of patients started
in some modality of haemodialysis (HD), 16.9% started
in peritoneal dialysis (PD) and 4.2% had an early kidney
transplantation. HD rates was 100.2 PMP, PD 21.6 PMP and
early kidney transplant 5.3 PMP. Again, a wide variation
tment modality in 2013.
Gender Initial treatment
PMP N PMP
ale Male Female HD PD ETX HD PD ETX
8 157 90.9 845 160 38 100.1 19 4.5
6 167.2 82.7 135 30 3 100.2 22.3 2.2
8 236.6 86.2 125 42 2 117 39.3 1.9
3 179.3 103.9 123 10 11 120.9 9.8 10.8
7 159.4 56.1 38 14 11 64.2 23.7 18.6
3 158.1 57.3 220 44 6 87.3 17.5 2.4
9 128.7 75.7 163 51 1 77.6 24.3 0.5
6 193 98.2 873 143 79 71.1 18.7 0.7
9 171.2 96.5 537 141 5 170.7 28 15.4
0 173.3 70.2 118 18 1 106.9 16.3 0.9
9 197.7 90.2 291 83 19 105.2 30 6.9
5 161.7 81.6 630 110 40 97 16.9 6.2
3 144.6 72.4 125 33 2 84.9 22.4 1.4
1 149.6 64.9 53 15 1 82.2 23.3 1.6
9 171.2 70.4 178 66 18 81.2 30.1 8.2
5 137.4 92.7 28 8 1 86.9 24.8 3.1
5 162.6 121.6 12 0 0 142.6 0 0
4 93 98.4 8 0 0 95.6 0 0
9 200.9 102.4 4502 968 238 100.2 21.6 5.3
N: total number of cases; PMP: patients per million of the population;
 of the Island of Menorca, which did not provide any data.
m neighbouring Morocco.
n e f r o l o g i a. 2 0 1 6;3 6(2):97–120 101
Table 3 – Incidence by age group in 2013 (PMP).
0–14 15–44 45–64 65–74 >75
Andalusia 6.5 39.6 172.8 399.8 387.4
Aragon 10.7 15.1 136.6 343.7 444
Asturias 0 38.9 193.9 386.8 362.8
Balearic Islands 0 33.2 180.6 524.6 579.7
Cantabria 0 52.3 124.7  388.3 159.1
Castile and León 0 23.9 107.2 315.6 276.6
Castile-La Mancha 0 26.1 140.1 243 378.1
Catalonia 11 34.3 162.7 470.6 535.1
Autonomous Community of Valencia 5.2 35.9 145.5 397.6 499.6
Extremadura 6.3 29.6 163.9 304.9 387.4
Galicia 0 39.3 172.2 365.5 331.2
Madrid 4.9 39.7 151.3 365 440.2
Murcia 3.8 38.7 147.4 399.6 366.8
Navarra 0 31.1 147.8 290.3 323.6
Basque Country 0 46.3 115.3 312.2 370.9
La Rioja 0 23.5 82.1 583.7 327.6
Ceuta 0 80.1 149 395.1 969.2
Melilla 0 79.9 51.8 467.7 517.3
Total in Spain 5 36 153.1 384.6 414.9









than 75 years (Table 5). However, the greatest percentage
of DM (33.9%) was in the group of 45 to 64 years of age,
and the percentage of UO increased with the age groupas observed among the different ARs (Table 2 and
ig. 2).
By PRD, 24.6% of incident patients had the diagnosis of dia-
etes mellitus (DM); classiﬁed as PRD of unknown origin (UO)
ere 20.9%; vascular diseases, including hypertension (vas-
ular and/or hypertensive nephropathy [VHN]), represented 16.2%; and glomerular disease (glomerulonephritis) were
nly 12.3% of incident patients (Table 5). DM was the most
ommon PRD (29.2%) in patients who  started RRT between
Table 4 – Age-adjusted incidence (EU27, 2005) 2013
(PMP).
Male Female Total
Ceuta 208.5 149 180.4
Balearic Islands 187.5 110.9 151.1
Catalonia 184.4 95.6 140.5
Melilla 111.1 142.6 128.4
Asturias 186.6 71.2 127.9




157.2  93.2 126.6
Madrid 163.1 83.4 122.2
Galicia 158.9 77.6 118.3
Murcia 155.7 79.3 118.2
Extremadura 152.6 67.7 111.8
La Rioja 126 88.9 108.6
Aragon 158.5 73 107.4
Basque Country 146 64 105
Navarra 136.8 63.2 101.2
Cantabria 149.8 51.8 100.9
Castile-La Mancha 120.3 71.2 97
Castile and León 124.4 46.1 86.8
Total in Spain 158.7 83.1 121.5
PMP: patients per million of the population.65 and 74 years old, and VHN (24.8%) and UO (27.8%) were
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Fig. 1 – Age-adjusted incidence 2013.
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Haemodialysis Peritoneal dialysis Early kidney transplantFig. 2 – Distribution of initial RRT modalities by AR.reaching a 40.7% in those over 75 years old (Table 6 and
Figs. 3 and 4).
The evolution of the overall incidence from 2007 to 2013
shows a sustained a gradual decrease from 127.4 PMP in 2007
Table 5 – Distribution of PRD in each age group. 2013.
GN (%) CPN/CIN (%) DM (%) VHN (%) PKD (%
0–14 14.71 17.7 0 2.9 5.9 
15–44 22.4 12.5 16.7 7.1 8.3 
45–64 16.5 8.4 26.5 10.7 13 
65–74 10.1 8.7 29.2 17.1 4.5 
>75 6 7.6 22.1 24.8 3 
Adults 12.3 8.7 24.7 16.3 7.2 
Total 12.3 8.8 24.6 16.2 7.2 
DM: diabetes mellitus; HDs: hereditary diseases; PRD: primary renal dis
lar and/or hypertensive nephropathy; CPN/CIN: chronic pyelonephritis/ch
unknown origin.
Table 6 – Distribution by age group of PRD. 2013.
GN (%) CPN/CIN (%) DM (%) VHN (%) PKD (%
0–14 0.7 1.2 0% 0.1 0.5 
15–44 21.1 16.6 7.9 5.1 13.4 
45–64 42.1 30.1 33.9 20.8 57.1 
65–74 21.3 25.8 30.8 27.3 16.3 
>75 14.9 26.4 27.4 46.7 12.7 
Total 100 100 100 100 100 
DM: diabetes mellitus; HDs: hereditary diseases; PRD: primary renal dis
lar and/or hypertensive nephropathy; CPN/CIN: chronic pyelonephritis/ch
unknown origin.;3  6(2):97–120
(in 2006 it was 130.6 PMP) down to 120.4 PMP  in 2012, with a
rise of 5.5%, up to 127.1, in 2013, which may be explained by
an increase in incidence in the most populared ARs: Andalusia
(5.2%), Catalonia (24.6%) and Madrid (14.8%), while in Valencia,
the fourth most populated, it decreased (−5.2%) (Table 7 and
Fig. 5).
The decrease in incidence occurred at the expense of HD as
an initial RRT, while the incidence of PD and early kidney trans-
plant progressively increased reaching 21.5 PMP  and 5.5 PMP,
respectively in 2013 (Table 8 and Fig. 5).
The PRD has been fairly stable. DM increased from 2007 to
2010, and it became the leading cause of RRT above UOs, then
it became stable around 24.5–25% of incident patients (Fig. 6).
On the other the incidence in PMP of DM continued to increase
every year. It should be taken into consideration that in the
last year, the data from the Canary Islands with a incidence of
DM as a PRD much greater than the rest of the ARs, was not
included in the analysis (Fig. 7).
Prevalence
On December 31st 2013 there were 50,567 patients on RRT
corresponding to a 95.3% of the total registry; the unadjusted
prevalence rate was 1125.7 PMP with a wide range among ARs.
The prevalence was less than 1000 PMP  in the Balearic Islands,
Cantabria, Madrid, Ceuta and Melilla, and greater than 1200 in
Catalonia, Valencia, Galicia and Murcia (Table 9). Among the
50,567 prevalent patients, 31,596 were men  (62.5%) and 18,971
were women (37.5%); this represents a rate of 1430 PMP  in men
and 831.2 PMP in women (Table 9); in Spain for every woman
in RRT, there were 1.67 men  This ration is varies from 1.25 in
) HDs (%) SDs (%) Other (%) UO (%) Total (%)
29.4 2.9 11.8 14.7 100
5.3 7.1 3.3 17.4 100
1.7 4.7 3.3 15.3 100
1% 4.8 3.6 21.1 100
0.5 4.4 3.94 27.9 100
1.6 4.9 3.6 20.9 100
1.7 4.9 3.6 20.9 100
ease; SDs: systemic diseases; GN: glomerulonephritis; VHN: vascu-
ronic interstitial nephropathy; PKD: polycystic kidney disease; UO:
) HDs (%) SDs (%) Other (%) UO (%) Total (%)
10.2 0.4 1.9 0.4 0.6
35.7 16.9 10.7 9.7 11.6
30.6 30.1 28.6 23 31.4
15.3 25.5 25.7 26.2 25.9
8.2 27.2 33 40.7 30.5
100 100 100 100 100
ease; SDs: systemic diseases; GN: glomerulonephritis; VHN: vascu-
ronic interstitial nephropathy; PKD: polycystic kidney disease; UO:
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Fig. 4 – PRD by age group 2013.
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Table 7 – Overall incidence, unadjusted rate 2007 to 2013 (PMP).
2007 2008 2009 2010 2011 2012 2013 Variation
2012–2013 (%)
Andalusia 117.9 125.6 118.8 116.6 114 117.5 123.6 5.2
Aragon 131.9 109.3 118.9 121 121.1 131.2 124.7 −4.9
Asturias 132.1 123.1 129.9 141.5 125.3 158.2 26.3
Balearic Islands 111.3 125.4 95  79.6 103.1 144.7  141.5 −2.2
Canary Islands 147.1 150.8 165.4  142.1 166.9 144
Cantabria 92.5 120.2 125.6 140.1 116.3 114.5 106.4 −7
Castile and León 124.2 124.7 120.1 116 115.7 123.3 107.1 −13.1
Castile-La Mancha 102.7 99.8 95.6 104.4 94.5 98 102.3 4.4
Catalonia 137.3 134.4 142.5 127.1 129.4 116.4 145 24.6
Autonomous Community of Valencia 146 128.6 138.4 137.3 129.8 141 133.6 −5.2
Extremadura 105.5 133 107.9 134.6 105.5 120 124.1 3.4
Galicia 139.2 147.3 124.5 135.1 141.7 132.3 142.1 7.4
Madrid 117.6 125 114.3 107.6 106.2 104.6 120.1 14.8
Murcia 108.8 108.5 108.7 0.2
Navarra 146.9 132.2 122.1 125.6 119.9 103.9 107.1 3
Basque Country 113 107.6 126.1 105.1 107.1 111.7 119.5 7
La Rioja 106.8 132.3 143 124.1 139.3 132.9 114.9 −13.5
Ceuta 326.4 336 266.9 211 194.2 142.8 142.6 −0.2
Melilla 331.2 279.9 122.5 118.4 140.2 210.4 95.6 −54.6
Total in Spain 127.4 128.1 126.5 121.1 120.7 120.4 127 5.5PMP: patients per million of the population.
Melilla to 2.27 in Cantabria. By age group, the greatest preva-
lence corresponded to the group from 65 to 74 years of age that
reached 3038.1 PMP  (Table 10 and Fig. 8).
The adjusted overall prevalence rate in 2013 was
1087.5 PMP; 1360.7 PMP  in males and 809.8 PMP in females
(Table 11 and Fig. 9).At the end of the year 2013 on 31 December 2013,
26,043 prevalent patients had a functioning kidney transplant
(51.5%), while 21,656 (42.8%) received treatment in HD centers,
4781 4884 4803 4594
656 688 718
754












Haemodialysis Peritoneal dialysis Earl
Fig. 5 – Evolution of incidence (PMP) overall and a78 (0.15%) were on home HD; 1667 (3.3%) received continu-
ous ambulatory peritoneal dialysis and 1120 (2.2%) received
cycling PD (Table 9).
Regarding PRD in the prevalent patients, glomerulonephri-
tis was the most common with 20.4% and 231 PMP,  followed by
UO (20.3% and 229 PMP) and DM (14.9% and 168 PMP), although
with marked differences among ARs (Figs. 10 and 11).
On December 31st 2013 among RRT patients on HD and PD
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Table 8 – Evolution of the percentage of the different initial RRT modalities 2007–2013.
2007  2008  2009  2010  2011  2012  2013
HD  (%)  PD  (%)  ETX  (%)  HD  (%)  PD  (%)  ETX  (%)  HD  (%)  PD  (%)  ETX  (%)  HD  (%)  PD  (%)  ETX  (%)  HD  (%)  PD  (%)  ETX  (%)  HD  (%) PD  (%)  ETX  (%)  HD  (%)  PD  (%)  ETX  (%)
Andalusia  89.2  10.1  0.7  88.3  10.1  1.7  86.4 11.4 2.2 89.1 8.3 2.6 86  11.7  2.3 81.9  14.7 3.4  81  15.3  3.6
Aragon 94.7  4.1  1.2  93.8  6.2  0  93.1 6.9 0  87.7 11  1.2 84  13.5  2.5 84.7  12.4 2.8  80.4  17.9  1.8
Asturias  82.4  15.5  2.1  85  12  3  85.1 14.9 0  81.8 13.9 4.4 79.7 17  3.3 75.6  23.7 0.7  74  24.9  1.2
Balearic
Islands
88.7 11.3 0  90% 10% 0% 91.2%  8.8%  0%  89.8%  8% 2.3%  81% 18.1%  1%  80.2%  14.8% 4.9%  85.4%  6.9%  7.6%
Canary
Islands
88.6 11.1 0.3  88.2  11.8  0  86.5 13.5 0  84.1 15.9 0 87.6 12.4  0  84.3  15.7 0
Cantabria  66 20.8  13.2  81.4  14.3  4.3  64.9 28.4 6.8 63.9 25.3 10.8 63.8 24.6  11.6 73.5  19.1 7.4  60.3  22.2  17.5
Castile  and
León
86.6  13.1  0.3  82.8  17.2  0  79.5 20.5 0  79.8 18.5 1.7 78.4 20.3  1.4 80.6  18.5 1 81.5  16.3  2.2
Castile-La
Mancha
86.2  12.3  1.5  86.8  12.3  1  89.4 9.5 1  84.5 15.1 0.5 80.5 18.5  1  81.7  18.3 0 75.8  23.7  0.5




91.3 7.9  0.8  91.5  7.3  0.8  90.1 7.9 2  85.2 11.7 3.4 83.9 15.2  0.9 79.4  17.3 3.3  78.6  20.6  0.7
Extremadura  90.4  9.6  0 84.2  15.8  0  84.9 15.1 0  88.6 11.4 0 84.6 15.4  0  87.2  12.8 0 86.1  13.1  0.7
Galicia  78.5  20.2  1.3  81.2  17.8  1  84.5 14.1 1.4 73.3 24.1 2.6 77.3 20.2  2.5 73.1  23.4 3.5  74  21.1  4.8
Madrid  83.6  13.7  2.7  83.7  14.9  1.4  82.9 14.2 2.9 82.9 14.7 2.4 81.9 14.5  3.6 81.6  13.8 4.6  80.8  14.1  5.1
Murcia 85.6 13.1 1.3  86.9  11.3 1.9  78.1  20.6  1.3
Navarra  89.9  10.1  0 84.1  15.9  0  85.7 14.3 0  91.3 11.3 0 76.6 18.2  5.2 76.1  19.4 4.5  76.8  21.7  1.4
Basque
Country
74  26 0 81  17.2  1.7  78.1 21.2 0.7 82.1 17.5 0.4 75.2 24.4  0.4 79.2  20  0.8  67.9  25.2  6.9
La  Rioja 81.8 18.2 0 85.7  14.3  0  100  0  0  37.5 32.5 0 80  20  0  79.1  20.9 0 75.7  21.6  2.7
Ceuta  100  0  0 100  0 0  100  0  0  100% 0 0 100  0 0  100  0  0 100  0 0
Melilla  100  0  0 100  0 0  100  0  0%  100% 0% 0 54.5 45.5  0  88.2  11.8 0 100  0 0
Total  in  Spain  86.4  11.9  1.7  86.1  12.1  1.7  84.8 12.7 2.6 83.3 13.7 2.9 82.2 15.1  2.7 80  16.5 3.5  78.9  16.9  4.2
PD:  peritoneal  dialysis  (all  modalities);  HD:  haemodialysis  (all  modalities);  RRT:  renal  replacement  treatment;  ETX:  early  kidney  transplant.
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Hereditary Systemic Other Unknown
Fig. 6 – Evolution from 2007 to 2013 of the percentage incidence of PRD.
The percentage of transplant patients that returned to dial-
ysis (HD or PD) due to transplant failure remained stable at
around 2.5% (Fig. 14).hepatitis B surface antigen (HBV+), 6.9% were positive for the
hepatitis C virus (HCV+) and 1.3% had positive serology for the
human immunodeﬁciency virus (HIV+).
The overall prevalence in Spain show a progressive increase
with values above 1000 PMP  since 2009 reaching 1125.8 PMP
in 2013 (Table 12 and Fig. 12). This increase, although it also
occurred in patients in HD, was markedly reﬂected in patients
with PD, and above all in transplant patients, who exceeded
50% starting in 2012 (Table 13 and Fig. 12).
Kidney  transplant
In Spain, during 2013, there were 2552 kidney transplants per-
formed in Spain, with a rate of 47.12 PMP.  Based on donor type,
382 (14.97%) were from a living donor and 200 (7.8%) were














Incidence of PRD Diabetes pmp
Fig. 7 – Evolution of the incidence of DM as PRD at the start
of RRT 2007–2013.criteria (asystole). In 67 cases the transplant recipient was a
child under 16 years of age (Table 14).
From 2007 to 2013, the number of kidney transplants
increased by 15.4%, and the rate PMP increased by more  than
5 points, from 48.9 PMP to 54.2 PMP. This increase is mostly
due to the increase in donations by living donors and in the






















Prevalence by age group
Prevalence Overall 1125.8 pmp
1318.6 in>15 years






















Table 9 – Prevalence by sex and initial renal replacement treatment modality in 2013.
Total Gender  Initial  treatment
N  PMP  N  PMP
Population  N PMP  Male  Female  Male  Female  CHD  HHD  CAPD  CPD  FTX  CHD  HHD  CAPD  CPD  FTX
Andalusia  8,440,300 9193  1089.2 5575 3618  1336.7 847.4 4104  9 0 384  4696  486.2  1.1 0  45.5 556.4
Aragon  1,347,150  1504  1116.4 972  532  1450.8 785.6 549  2 65 5  883  407.5  1.5 48.3 3.7 655.5
Asturias  1,068,165 1209  1131.8 783 426  1531.3 765.1 430 0 51 62  666  402.6  0  47.7 58  623.5
Balearic
Islandsa
1,017,395  945  928.8 598  347  1178.3 680.5 460  0 0 45  440  452.1  0  0  44.2 432.5
Cantabria  591,888  569  961.3 395  174  1368.5 573.8 174  2 29 7  357  294  3.4 49  11.8 603.2
Castile  and
León
2,519,875  2634  1045.3 1731  903  1388.8 709.1 1051  2 100  67  1414  417.1  0.8 39.7 26.6 561.1
Castile-La
Mancha
2,100,998  2150  1023.3 1324  826  1252.6 791.2 811  3 80 44  1212  386  1.4 38.1 20.9 576.9




5,113,815 6295  1231  3889  2406  1534.4 932.8 3325  10 351  46  2563  650.2  2  68.6 9 501.2
Extremadura 1,104,004 1194  1081.5 735 459  1341.1 825.6 580  8 50 23  533  525.4  7.2 45.3 20.8 482.2
Galicia  2,765,940  3361  1215.1 2109  1252  1579.6 875  1473  7 193  88  1600  532.5  2.5 69.8 31.8 578.5
Madrid  6,495,551  6490  999.1 3991  2499  1277.6 741.1 2492  15 267  84  3632  383.6  2.3 41.1 12.9 559.2
Murcia  1,472,049  1767  1200.4 1111  656  1501.7 895.9 896  0 86 7  778  608.7  0  58.4 4.8 528.5
Navarra 644,477 753  1168.4 519 234  1617.2 723.2 271  4 11 20  447  420.5  6.2 17.1 31  693.6
Basque
Country
2,191,682  2457  1121.1 1567  890  1466.2 792.6 741  3 164  28  1521  338.1  1.4 74.8 12.8 694
La  Rioja  322,027  369  1145.9 233  136  1454.8 840.2 145  2 9 17  196  450.3  6.2 27.9 52.8 608.6
Ceutab 84,180  81  962.2 54  27  1254.1 656.6 81  0 0 0  0  962.2  0  0  0 0
Melillab 83,679 63  752.9 35  28  813.6 688.6 63  0 0 0  0  752.9  0  0  0 0
Total  in  Spain  44,916,825  50,567  1125.8 31,596  18,971  1430.1 831.2 21,658  75 1666  1120  26,048  482.2  1.7 37.1 24.9 579.9
CPD:  cycling  peritoneal  dialysis;  CAPD:  continuous  ambulatory  peritoneal  dialysis;  CHD:  centre  haemodialysis;  HHD:  home  haemodialysis;  N:  total  number  of  cases;  PMP:  patients  per  million  of the  population;
FTX:  functioning  kidney  transplant.
a The  population  covered  on  the  Balearic  Islands  excludes  the population  of  the  Island  of  Menorca,  which  did not  provide  any  data.
b The  autonomous  cities  of  Ceuta  and  Melilla  provide  care  for  patients  from  neighbouring  Morocco.
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Table 10 – Prevalence by age group in 2013 (PMP).
0–14 15–44 45–64 65–74 >75
Andalusia 34 455.9 1723.5 3090.4 2654.3
Aragon 37.4 395.4 1644.5 2674.1 2474.9
Asturias 51.7 412 1544.8 2348.7 2140.8
Balearic Islands 0 241.6 1348.7 2968.3 3577.3
Cantabria 0 431.6 1461.3  2543.2 1479.9
Castile and León 0 363.3 1477.3 2374.9 1960.1
Castile-La Mancha 3.1 373.1 1615.6 2984.7 2358.3
Catalonia 58.1 447.9 1846.3 3586 3288.1
Autonomous Community of Valencia 56.1 426.9 1726.7 3250.6 3409.2
Extremadura 6.3 423.3 1737.9 2492 2181.5
Galicia 27.5 471.7 1761.5 2855.2 2004.2
Madrid 36.5 376.3 1524.3 2864.9 2734.7
Murcia 34.6 421.5 1978.4 3606 3762.4
Navarra 0 267.9 1324.4 3084.3 4692.8
Basque Country 56.1 483.6 1524.7 2819.5 2134.9
La Rioja 0 516.2 1525.2 3392.9 2382.6
Ceuta 0 160.2 1837.5 4938.8 3150
Melilla 0 372.9 1139.1 2338.6 4397.3
Total in Spain 36.3 419.4 1669 3038.1 2712
PMP: patients per million of the population.MortalityThe overall mortality of patients in RRT remained sta-











































Fig. 9 – Age-adjusted prevalence 2013.Mortality remain stable in the three modalities of RRT (HD, PD
and transplant), although there was a very modest increase
in mortality in transplant patients, which continues to be the
lowest of the 3 modalities (Table 16).
Survival
Between 2004 and 2012 there were 40,394 incident patients
that met  the selection criteria. Tables 17 and 18 show the dis-
tribution by AR and year.
Table 19 shows the main characteristics of the sample.
Estimated median survival was 6.2 years, with a 95% con-




































of the Basque Country
Ceuta
Spain
Diabetes mellitus. Prevalentes (pmp)
Fig. 10 – DM as PRD in prevalent patients in RRT PMP,
according to AR 2013.
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Table 11 – Age-adjusted prevalence (EU27, 2005) 2013
(PMP).
Male Female Total
Murcia 1600.8 971 1294.8
Catalonia 1555.6 917 1238.4




1439  902.9 1177.6
Andalusia 1351.1 874 1113.9
La Rioja 1351.8 812 1091
Navarra 1455.8 678.1 1081.9
Galicia 1342.7 777.7 1058.6
Aragon 1291.5 726.5 1017.5
Madrid 1298.1 752.8 1016




Extremadura 1231 779.7 1011.2
Melilla 1004.9 956.8 989
Balearic Islands 1218.6 726.3 982.2
Asturias 1256.4 649.5 946.8
Cantabria 1241.6 547 893.6
Castile and León 1146.5 615.1 889.7










































Diabetes mellitus, % prevalent
Fig. 11 – Percentage of DM among prevalent patients in
Discussion  and  conclusionsPMP: patients per million of the population.
The unadjusted probability of survival was 91%, 81% and
7% after one, 2 and 5 years, respectively, as shown in Table 20.
Table 21 presents the adjusted survival analysis; those vari-
bles that had turned out to be signiﬁcant in the univariate
nalysis were included as potential predictive factors.The Cox model shows the following as independent factors
f survival: age, diabetes as PRD, transplanted, sex and modal-
ty of initial RRT (Table 21), survival being worse for diabetic
Table 12 – Overall prevalence, unadjusted rate PMP  2007 to 201
2007 2008 
Andalusia 952.9 960.3 
Aragon 789.7 950.3 
Asturias 1077.3 973.9 
Balearic Islands 496.9 434.2 
Canary Islands 994.6 607.4 
Cantabria 844.9 834.9 
Castile and León 935.8 965.5  
Castile-La Mancha 927 911.4 
Catalonia 1099.1 1123.7 
Autonomous Community of Valencia 1103.8 1098.9 
Extremadura 893.6 920.1 
Galicia 1047.8 1061.4 
Madrid 971.6 1077.2 
Murcia 
Navarra 485.2 486.8 
Basque Country 959.9 1016.6 
La Rioja 987.2 1124.4 
Ceuta 900.7 969.1 
Melilla 1022.5 1007.7 
Total in Spain 985.3 994.8 
PMP: patients per million of the population.RRT, according to AR 2013.
men  over 45 years of age who had started RRT with HD and
who had not undergone a transplant.
Fig. 15 shows the survival curves for the incident patients
during the period 2004–2012 based on age group.Over the course of these 7 years, the REER was able to collect
and assemble information about a percentage above 95% of
3 (PMP).
2009 2010 2011 2012 2013
977.4 1004.1 1028.4 1054.1 1089.2
998.2 994.7 1028.8 1071.5 1116.4
990.5 1030.1 1069.3 1131.8
588.1 792 886.8 877.2 928.8
1169.2 1143.3 680.4 1162.7
874 883.1 891.9 931.2 961.3
994.3 1010.7 1014.7 1038.9 1045.3
929.2 964.6 997.5 1004.3 1023.3
1158.5 1188.4 1222.9 1200.1 1262
1107.2 1130.9 1147.3 1195.1 1231
952.5 999.8 1026.7 1049.5 1081.5
1079 1125.9 1171.6 1178.1 1215.1
907.8 926.7 956.6 970.1 999.1
1117.6 1153 1200.4
472.6 500.8 1151 1137.2 1168.4
1024.8 1019.6 1055.6 1093 1121.1
1038.2 1045.2 1136.4 1072.3 1145.9
1004.1 1092.1 1031.9 1023.6 962.2
803.2 789.1 828.3 841.6 752.9






















Table 13 – Evolution of the percentage of the different RRT modalities in prevalent patients 2007–2013.
2007 2008 2009 2010 2011 2012 2013
HD (%) PD (%) TX (%) HD (%) PD (%) TX (%) HD (%) PD (%) TX (%) HD (%) PD (%) TX (%) HD (%) PD (%) TX (%) HD (%) PD (%) TX (%) HD (%) PD (%) TX (%)
Andalusia 48.6 4.5 46.9 48.9 4.1 47 48.2 4.3 47.5 47.7 4.3 47.9 46.1 4.3 49.6 45.1 4.4 50.5 44.7 4.2 51.1
Aragon 50.5 0.8 61.8 42 1.1 56.9 44.7 1.5 53.8 44.3 2.8 53 40.2 3.7 56.1 39.3 4.3 56.4 36.6 4.7 58.7
Asturias 32.7 4.5 51.2 37.4 5.4 57.2 37.3 5.7 57 37.7 5.8 56.5 37.4 5.9 56.6 35.7 9 55.3 35.6 9.3 55.1
Balearic
Islands
91.5 8.5 91 9 92.6 7.4 47.1 3.8 49.1 44.7 4.5 50.7 47.9 4.9 47.3 48.7 4.8
Canary
Islands
54.4 4.4 41.1 91.8 8.2 72.7 50.5 5 44.5 51.6 5.8 42.6 89.7 10.3 49.2 5.3 45.4
Cantabria 36.4 9.5 54.1 38.3 7 54.7 37.5 7.4 55.1 34.4 7.5 58.1 32.5 7.6 59.9 32.5 6.7 60.8 30.9 6.3 62.7
Castile and
León
45.4  5.5 49.1 44.8 5.9 49.3 43.9 6.5 49.6 42.8 6.5 50.7 42 7 51 41.1 6.5 52.5 40 6.3 53.7
Castile-La
Mancha
43 5.2 51.8 41.5 3.9 54.7 41.3 3.8 55 41.3 4.5 54.2 41% 5.1 53.9 39.2 5.7 55.1 37.9 5.8 56.4





56.5 4.3 39.2 56.7 3.8 39.3 56 3.5 40.5 56.2 3.4 40.3 55.2 4.9 39.8 54.6 5.5 40 53 6.3 40.7
Extremadura 49 5.9 45.2 48.6 6 45.3 48.9 6.2 45 50.6 5.9 43.5 49.3 5.8 45 49.2 6.4 44.5 49.3 6.2 44.5
Galicia 43.3 9.2 47.5 45.8 9.4 44.8 46.1 8.6 45.3 45.8 8.8 45.4 45 8.7 46.3 44.6 8.2 47.2 44 8.4 47.6
Madrid 35.5 7.3 57.2 36.4 5.1 58.4 41.4 5.9 52.7 40.4 5.7 53.9 39 5.5 55.5 38.5 5.6 56 38.6 5.4 56
Murcia 55.6 4 40.4 53.5 4.3 42.2 50.7 5.3 44
Navarra 89.5 10.5 111.2 90.4 11.3 117.9 78.2 12.8 0 89 11.3 123.2 37.8 5.1 57.1 37.1 4.8 58.1 36.5 4.1 59.4
Basque
Country
30 8.3 61.7 31.5 7.7 60.8 29.6 7.8 62.6 31.5 8.1 60.4 31.5 8.7 59.8 31.2 8.2 60.6 30.3 7.8 61.9
La Rioja 37.7 4.9 57.4 37.3 4.5 51.3 44.9 3.3 51.8 41.2 8 55.8 39.5 6.8 53.7 42.9 8.6 48.4 39.8 7 53.1
Ceuta 100 0 100 0 100 0 100 0 100 0 100 0 100 0
Melilla 100 0 97.2 0 100 0 100 0 96.9 3.1 97.1 2.9 100 0
Total in Spain 46.2 5.3 49.3 47.1 5 50.8 46.5 5 48.5 46 5.1 49.8 45.6 5.4 49 43.7 5.4 50.9 43 5.5 51.5
PD: peritoneal dialysis; HD: haemodialysis; RRT: renal replacement treatment; TX: transplant.
n e f r o l o g i a. 2 0 1 6;3 6(2):97–120 111
Table 14 – Kidney transplants by AR of the transplant centre. 2013.
AR/HOSPITAL Total in 2013 Chi Asyst Living DK EB
Andalusia 412 11 32 60 3
Aragon 85 11
Asturias 48 5 1
Balearic Islands 39
Canary Islands 101 3 12
Cantabria 61 4 6
Castile-La Mancha 94 6 0 2
Castile and León 108 6 3
Catalonia 540 21 25 165 1 1
Autonomous Community of Valencia 237 7 13 8 4
Extremadura 30
Galicia 132 2 28
La Rioja 16 1
Madrid 406 19 104 40 2
Murcia 61 4
Navarra 26 2
Basque Country 156 9 4 38
Total in Spain 2552 67 200 382 9 5
Asyst: transplant from a deceased donor in asystole; EB: en bloc double kidney transplant from a child donor; DK: double kidney transplant and
older donor; AR: autonomous region; Chi: transplant in children under 15 years of age; Living: transplant from a living donor.
Table 15 – Kidney transplants overall and by AR 2007–2013.
Autonomous region 2007 2008 2009 2010 2011 2012 2013
Andalusia 344 367 381 330 426 457 412
Aragon 63 55 66 65 74 68 85
Asturias 54 40 46 43 53 50 48
Balearic Islands 28 46 45 43 43 52 39
Canary Islands 145 126 103 104 116 91 101
Cantabria 41 27 46 42 48 36 61
Castile-La Mancha 36 51 51 54 59 55 94
Castile and León 83 86 79 93 85 117 108
Catalonia 470 471 524 460 581 559 540
Autonomous Community of Valencia 231 198 209 209 190 232 237
Extremadura 30 35 33 32 44 34 30
Galicia 96 120 127 131 146 138 132
La Rioja 10 5 16
Madrid 395 407 417 420 406 432 406
Murcia 52 45 48 47 54 76 61
Navarra 18 26 35 25 40 32 26
Basque Country 125 129 118 127 123 117 156
Total in Spain 2211 2229 2328 2225 2498 2551 2552
Total in Spain (PMP) 48.92 48.29 49.80 47.32 52.93 53.97 54.15
Living donor transplants 137 156 235 240 312 361 382
Transplants from a donor in asystole 104 105 145 158 140 201 200
Transplants in Children 72 62 62 58 63 59 67
AR: autonomous region; PMP: patients per million of the population.
Table 16 – Evolution of annual mortality 2007–2013, by treatment modality (%).
2007 2008 2009 2010 2011 2012 2013
Mortality in HD 15.27 14.52 14.79 14.60 14.12 14.43 15.1
Mortality in PD 8.79 10.54 8.44 8.13 8.07 8.85 8.86
Mortality in TX 1.64 1.50 1.89 1.67 1.85 2.31 2.35
Overall 8.46 8.34 8.36 8.24 7.78 7.96 8.18
PD: peritoneal dialysis; HD: haemodialysis; TX: transplant.
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Haemodialysis Peritoneal dialysis Functioning kidney transplant Prevalence PMP
rall aFig. 12 – Evolution of prevalence (PMP) ove
the population of Spain reaching 100% in 2012, this is despite
the occasional difﬁculties of some of the autonomous region
registries. Therefore, the future objective should be to cover
100% of the population every year, with a tendency to group
individualised data from an ever greater number of registries,
until a total coverage throughout Spain is achieved. Likewise,
the quality of data collected is improved, as demonstrated by
the temporal coherence of the data.
Annual incidence sustained a gradual decrease, although
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BD donor Living kidney donor As
Fig. 13 – Evolution of the number of transplantsnd according to RRT modality 2007–2013.
a result of either a change in the trend or simply a temporary
isolated increase. The evolution of incidence in the different
varieties of RRT showed the marked decrease in HD as an
initial treatment, which went from 86.4% in 2007 to 78.9% in
2013, while the percentage of patients who started RRT with
PD increased from 11.9% in 2007 to 16.9% in 2013, and those
who had undergone a transplant without previous treatment
with HD or PD increased from 1.7% in 2007 to 4.2% in 2013.
The total number of prevalent patients with ESRD in RRT















ystole donation Kidney transplant PMP
 according to donor type. BD: brain death.
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Table 17 – Distribution by AR of the incident patients







Castile-La Mancha 1943 (4.8)
Castilla y León 2697 (6.7)
Catalonia 8539 (21.1)




Basque Country 2159 (5.3)
Total 40,394 (100)
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20-44 years 15-19 years 45-64 years
65-74 years 75-...years
Fig. 15 – Survival of incident patients in the period
2004–2012 for the different age groups.
Table 18 – Distribution by year of the incident patients
2004–2012 included in the survival analysis.










wan, 2365 PMP in Japan and 1976 PMP in United States, whileollowing kidney transplant failure.
010, essentially owing to an increase in functioning kidney
ransplants, which represented 49.3% in 2007 and 51.5% in
013.
nternational  comparisons
omparisons were made with countries with international
egistries available when the present manuscript was writ-
en. The latest USRDS report20 included data on 2012 and the
volution of the epidemiological data for ESRD from 2006 to
012.
ncidence
he incidence rate of the countries whose data were col-
ected by the USRDS in 2012 ranged from 25 PMP  in Ukraine
o 450 in Taiwan and 467 in Jalisco (Mexico). Spain (121 PMP)
as in the below the middle of the table, with numbers
imilar to those of western European countries with simi-
ar characteristics (Fig. 16). In these seven years there was
 3.1% decrease, in the same range that Australia (−3.1%),
anada (−4.5%), the Netherlands (−3.3%), Norway (−3.9%) and
srael (−3.9%). Some European countries experienced an even
ore  marked decrease in incidence: Austria (−10.3%), CzechTotal 40,394 (100)
N: number of cases.
Republic (−7.2%), Denmark (−9.7%), Finland (−7.6%) and Swe-
den (−7.9%) (Fig. 17).
The percentage of DM as PRD varied widely among
countries (Fig. 18), with the highest rates in Singapore (66%),
Malaysia (61%) and Jalisco (Mexico) (59%), while it represented
less than 20% in Flemish Belgium, Russia, Norway, the Nether-
lands, Romania and Ukraine.
Prevalence
The prevalence at December 31st 2012 was 2902 PMP  in Tai-in Bahrain, Qatar, Indonesia, Russia, South Africa and Ukraine
less than 300 PMP received RRT; Spain, with 1091, was in
the upper third of the table In the majority of western
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Fig. 16 – Unadjusted incidence rate (PMP) by country in
2012.
Source: United States Renal Data System, 2014 Annual Data
Report: Epidemiology of Kidney Disease in the United
States. 2014. Bethesda, MD:  National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney
Diseases (2014). Special analyses, USRDS ESRD Database.
Data presented only for countries from which relevant
information was available. All rates are unadjusted. UˆK:
England, Wales and Northern Ireland (Scotland data
reported separately). Japan and Taiwan are dialysis only.
Data for Belgium do not include patients younger than 20.
Data for Indonesia represent the West Java region. Data for






































Fig. 17 – Evolution of the ESRD incidence rate (PMP) by
country, 2000 to 2012, in countries whose incidence rate
decreased by at least 3% from 2006 to 2012.
Source:  United States Renal Data System, 2014 Annual Data
Report: Epidemiology of Kidney Disease in the United
States. 2014. Bethesda, MD: National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney
Diseases (2014). Special analyses, USRDS ESRD Database.
All rates are unadjusted. Data are shown for countries withEuropean countries the range was between 808 PMP in Finland
to 1670 PMP  in Portugal (Fig. 19). From 2006 to 2012 Spain unad-
justed prevalence increased by 12.9%, similar to the countries
around i (Fig. 20), although the prevalence of treatment with
dialysis has decreased by 0.4% with the consequent increase inincidence increase or decrease from 2006 to 2012 or 2011.
the numbers of transplanted patients and with a functioning
graft.
Transplants
In accordance with the 2014 USRDS report,20 there was major
variability in transplant rates among reporting countries,
which did not only reﬂect the variations in incidence and
prevalence reported. The highest transplant rate reported,
60 PMP in Norway, was 30 times higher than the lowest trans-
plant rate reported, 2 PMP in Ukraine. The highest rates of
kidney transplant for all donor types were those reported by
Norway (60 PMP), Jalisco (Mexico) (59 PMP), the Netherlands
(57 PMP), the United States (55 PMP), Croatia (54 PMP) and Spain
(54 PMP) (Fig. 21): Although, according to the data of the Global
Observatory on Donation and Transplantation (GODT),21 the
highest rate of kidney transplant from a deceased donor is
50.5 PMP in Croatia followed by Spain (46.8 PMP), Belgium
(44.4 PMP), Estonia (43.9 PMP) and Norway (43.6 PMP) (Fig. 22).
The evolution of the annual rate of transplants from 2006 to
2012 showed an increase in the overall rate in countries of the
European Union and all countries of the World Health Orga-
nization that reported to the GODT21 (Table 22). The increase
observed in Spain is comparatively much higher, with an 18.3%





































































































Fig. 18 – Percentage of incident patients with ESRD, in
whom diabetes mellitus was the primary renal disease, by
country, in 2012.
Source: United States Renal Data System, 2014 Annual Data
Report: Epidemiology of Kidney Disease in the United
States. 2014. Bethesda, MD:  National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney
Diseases (2014). Special analyses, USRDS ESRD Database.
Data presented only for countries from which relevant
information was available. UˆK: England, Wales and
Northern Ireland (Scotland data reported separately). Data
for Spain include 18 of 19 regions. Data for France include
22 regions. Data for Indonesia represent the West Java
region. Data for Belgium do not include patients younger
than 20. There were  zero ESRD patients in Iceland with
diabetes as the primary ESRD cause in 2012. Abbreviations:
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Fig. 19 – Prevalence of ESRD in RRT, PMP  by country, in
2012.
Source:  United States Renal Data System, 2014 Annual Data
Report: Epidemiology of Kidney Disease in the United
States. 2014. Bethesda, MD:  National Institutes of Health,
National Institute of Diabetes and Digestive and Kidney
Diseases (2014). Special analyses, USRDS ESRD Database.
Data presented only for countries from which relevant
information was available. All rates are unadjusted and
reﬂect prevalence at the end of 2012; rates for Colombia and
Lebanon reﬂect prevalence at the end of June 2012. UˆK:
England, Wales and Northern Ireland (Scotland data
reported separately). Japan and Taiwan include dialysis
patients only. Data for Belgium do not include patients
younger than 20. Data for Indonesia represent the West
Java region. Data for Spain include 18 of 19 regions. Data for
France include 22 regions. Data for Turkey in 2012 was
collected with the collaboration of the Ministry of Health,
which collects patient-based data; however, in previous
years center-based data were reported. Abbreviations:
ESRD: end-stage renal disease; sp.: speaking.
116  n e f r o l o g i a. 2 0 1 6;3  6(2):97–120







Under 20 166 0.4
20 to <45 5086 12.6
45 to <65 12,826 31.8
65 to <75 10,923 27
75+ 11,393 28.2














recovery of renal function




SD: standard deviation; N: number of cases; IQR: interquartile range;
RRT: renal replacement treatment.
Table 20 – Unadjusted survival.
Years N of events N who entered in the interval N at risk Survival (%) 95% CI
1 3422 40,394 37,936 91 90.8–91.2
2 3319 32,057 29,930 81 80.6–81.4
3 1250 12,980 11,500 57 56.6–57.4
N: number of cases; 95% CI: 95% conﬁdence interval.
Table 21 – Cox model.
Variable HR 95% CI p
Age group
15–19 years 0.47 0.20–1.14 0.96
20–44 years 1 – 0.000
45–64 years 2.7 2.41–2.99 0.000
65–74 years 4.44 3.99–4.93 0.000
≥75 years 6.35 5.71–7.06 0.000
Diabetes as PRD 1.28 1.23–1.33 0.000
Female sex 0.86 0.83–0.90 0.000
PD as initial RRT 0.91 0.85–0.96 0.001
Transplant 0.16 0.15–0.18 0.000
PD: peritoneal dialysis; PRD: primary renal disease; HR: hazard ratio;
95% CI: 95% conﬁdence interval; RRT: renal replacement treatment.
survival of patients in RRT were limited by differences in the
methodology used for analysis and data processing as well as
differences in the analysis of cohorts followed through differ-
ent periods of time.increase in total kidney transplants, with the extraordinary
contribution of transplants from a living donor (253.9%) and
from deceased donors in asystole (107.2%).
Survival
Comparisons with international data20,22 with respect to the
















































Fig. 20 – Trend in the prevalence of ESRD in RRT, PMP  by country, in 2012.
Source: United States Renal Data System, 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States.
2014. Bethesda, MD:  National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (2014).
Table 22 – Evolution of kidney transplants 2006–2012.
EU27 UE28 % increase
2006–2012
2006 2007 2008 2009 2010 2011 2012
Population 488.42 492.3 493 500 501.6 504.2 507.5 3.9
Total kidney TXs 16,819 17,306 17,198 17,886 18,246 18,712 19,085 13.5
TX from living donor 2617 2926 3089 3354 3616 3857 3970 51.7
TX from deceased donor 14,204 14,380 14,109 14,532 14,630 14,855 15,115 6.4
TX from donor in asystole 598 707 837 1007 1037 1178 1400 134.1
Total TXs PMP 34.4  35.2 34.9 35.8 36.4 37.1 37.6 9.2
Living donor TX PMP 5.4 5.9 6.3 6.7 7.2 7.6 7.8 46
TX from deceased donor PMP 29.1 29.2 28.6 29.1 29.2 29.5 29.8 2.4
TX from donor in asystole PMP 1.2 1.4 1.7 2 2.1 2.3 2.8 125.3
Spain
Population 44.7 45.2 46.2 46.75 47 47.2 46.8 4.7
Total kidney TXs 2157 2211 2229 2328 2225 2498 2551 18.3
TX from living donor 102 137 156 235 240 312 361 253.9
TX from deceased donor 2055 2074 2073 2093 1985 2186 2190 6.6
TX from donor in asystole 97 104 105 148 158 140 201 107.2
Total TXs PMP 48.3 48.9 48.2 49.8 47.3 52.9 54.5 13
Living donor TX PMP 2.3 3 3.4 5 5.1 6.6 7.7 238
TX from deceased donor PMP 46 45.9 44.9 44.8 42.2 46.3 46.8 1.8
TX from donor in asystole PMP 2.2 2.3 2.3 3.2 3.4 3 4.3 97.9
103 Member countries of the World Health Organization that provided data to the GODT
Total kidney TXs 65,700 65,511 68,250 69,214 71,418 73,179 76,118 15.9
GODT: Global Observatory on Donation and Transplantation; PMP: patients per million of the population; TX: transplant.















































































































Fig. 21 – Rate of kidney transplant, PMP,  by country, in 2012.
Source: United States Renal Data System, 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States.
2014. Bethesda, MD:  National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases (2014).
Special analyses, USRDS ESRD Database. Data presented only for countries from which relevant information was available.
All rates are unadjusted. UˆK: England, Wales and Northern Ireland (Scotland data reported separately). Data for Belgium do
not include patients younger than 20. Data for France include 22 regions. Data for Spain include all regions. There is
underreporting of prevalent transplant patients in Turkey. Abbreviations: sp.: speaking.









































































































Rate (PMP) Kidney Tx LD
Rate (PMP) Tx Kidney DD
Fig. 22 – Rate of kidney transplant, PMP,  by country, in 2013, according to donor type. DD: deceased donor; LD: living donor.
Source: Global Observatory on Donation and Transplantation (GODT). Organ Donation and Transplantation Activities 2012.
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Annex  1.  REER  members
Spanish Transplant Organisation: Eduardo Martín-Escobar,
Beatriz Mahillo Durán; Spanish Society of Nephrology (SEN):
J. Emilio Sánchez, Ramón Saracho Rotaeche; Andalusia Renal
Registry (SICATA): Pablo Castro de la Nuez, Miguel Ángel Gentil
Govantes; Aragon Renal Registry: José M.  Abad Diez, José Igna-
cio Sánchez Miret; Asturias Renal Registry: Ramón Alonso de la
Torre, José Ramón Quirós García; Balearic Islands Renal Reg-
istry: Catalina Garrigó; Valencia Renal Registry (REMRENAL):
Manuel Ferrer-Alamar, Oscar Zurriaga Llorens; Cantabria
Renal Registry: Manuel Arias, Óscar García Ruiz; Castilla-La
Mancha Renal Registry: Gonzalo Gutierrez Ávila, Inmaculada
Moreno Alía; Castilla y León Renal Registry: Raquel Gonzalez
Fernández, José María Monfá Bosch; Catalonia Renal Registry:
Jordi Comas Farnes, Emma  Arcos Fuster; Extremadura Renal
Registry: María A. García Bazaga, Julian Mauro Ramos Aceitero;
Galicia Renal Registry: Encarnación Bouzas Caaman˜o, Teresa
García Falcón, Jacinto Sánchez Iban˜ez; La Rioja Renal Registry:
Enma Huarte-Loza, Marta Artamendi Larran˜aga; Madrid Renal
Registry (REMER): Manuel Aparicio Madre, José A. Herrero;
Murcia Renal Registry: Carmen Santiuste de Pablos; Navarra
Renal Registry: Jesús Arteaga Coloma; Basque Country Renal
Registry: Angela Magaz Lago, In˜igo Moina Eguren.
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